Summary:
You have been asked to participate in this study because you have Active Ulcerative Colitis (UC). The study drug is a novel (first-in-class small molecule) oral study treatment for UC. NX-13 activates the Nod-like receptor X1; (NLRX1), which may improve the condition of the bowel.
Qualified Participants Must:
• Have diagnosis of UC for 90 days or more prior to screening.
• Other criteria will apply. Details will be provided.
Qualified Participants May Receive:
You will receive up to $100 following each completed study visit.